title: Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. World Health Organization.
abstract: OBJECTIVE
  To compare two regimens of mifepristone plus gemeprost for early pregnancy termination.
  
  
  METHODS
  A prospective, randomized, multicenter trial.
  
  
  METHODS
  Ten gynecological services, mostly in academic hospitals.
  
  
  METHODS
  Three hundred eighty-five healthy women up to 35 years of age with amenorrhea less than or equal to 49 days requesting pregnancy termination.
  
  
  METHODS
  Mifepristone, 25 mg five times at 12-hour intervals (n = 192) or 600 mg as a single dose (n = 193) followed by 1 mg gemeprost 60 hours after the start of mifepristone.
  
  
  METHODS
  Pregnancy outcome, time of onset and duration of vaginal bleeding, subjective complaints, and hormone changes during treatment and 6-week follow-up.
  
  
  RESULTS
  Treatment outcome was identical in both groups with an overall complete abortion rate of 92.7% among the 385 women included in the analysis. The frequency of complaints, bleeding patterns, and changes in hemoglobin, beta-human chorionic gonadotropin, estradiol, and progesterone were also similar in both groups. Cortisol (at 12 and 36 hours after mifepristone) and prolactin (at 12 hours) were significantly higher in the single 600-mg dose group.
  
  
  CONCLUSIONS
  When used for early pregnancy termination with prostaglandin, a lower dose of mifepristone than the currently recommended single 600-mg dose may suffice.
mesh_terms: D000028:Abortion, Induced; D000328:Adult; D000527:Alprostadil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002681:China; D006063:Chorionic Gonadotropin / Q000097:blood; D018997:Chorionic Gonadotropin, beta Subunit, Human; D004958:Estradiol / Q000097:blood; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D015735:Mifepristone / Q000008:administration & dosage* / Q000009:adverse effects; D010446:Peptide Fragments / Q000097:blood; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D011446:Prospective Studies; D011897:Random Allocation
chemical_list: D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D006454:Hemoglobins; D010446:Peptide Fragments; D015735:Mifepristone; C021182:gemeprost; D011374:Progesterone; D004958:Estradiol; D011388:Prolactin; D000527:Alprostadil; D006854:Hydrocortisone